Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038323 · ClinicalTrials.gov registry record · Phase 4
Drug and Talk Therapy for Fibromyalgia
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT01038323 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 58 participants.
The verdict
NCT01038323, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
Fibromyalgia Syndrome (FMS) afflicts 2% of the U.S. population and have huge individual and societal costs in terms of quality of life, social and work functioning, health care use, and lost productivity. Although single therapy approaches such as medication, graduated exercise, and Cognitive Behavioral Therapy (CBT) are well-established treatment approaches, the majority of FMS continue to report significant levels of pain and pain-related disability. Testing the efficacy of using combination therapies such and CBT with medication has considerable potential to maximize treatment response. Also, exploring the biological and psychological mechanisms underlying combination treatment may pave the way for developing new treatments for FMS sufferers. We chose to study drug and CBT for several reasons: 1) the scarcity of trials that manipulate medications along with CBT in FMS, 2) the prohibitive nature of adding an exercise treatment arm in a study that has both time and budgetary constraints, 3) the complexity in understanding the mechanism of actions of 3 different modes of intervention in one clinical trial, and 4) the desire to explore mechanisms in this program of research, in particular the potential effects of a biological intervention (drug) on what is traditionally considered a psychological outcome (pain-related attributions and cognition) and the potential effects of a psychological intervention (CBT) on what is traditionally considered a physiological outcome (pain sensitivity).
Interventions
- OTHER CBT and milnacipran
- BEHAVIORAL CBT with a placebo
- DRUG Educational with milnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01038323
The ClinicalTrials.gov registry entry for NCT01038323 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CBT and milnacipran is the first listed.
NCT01038323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01038323 about?
NCT01038323 is a clinical study titled "Drug and Talk Therapy for Fibromyalgia". Fibromyalgia Syndrome (FMS) afflicts 2% of the U.S. population and have huge individual and societal costs in terms of quality of life, social and work functioning, health care use, and lost productivity. Although single therapy approaches such as medication, graduated exercise, and Cognitive Behavi...
What is the current status of trial NCT01038323?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2009-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01038323?
The interventions under investigation include: CBT and milnacipran (OTHER), CBT with a placebo (BEHAVIORAL), Educational with milnacipran (DRUG).
Who is sponsoring clinical trial NCT01038323?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.